Two Doses of Polatuzumab Vedotin in Patients With Relapsed/Refractory Follicular Lymphoma
June 11th 2015Catherine M. Diefenbach, MD, assistant professor, Department of Medicine, NYU Langone Medical Center, discusses the efficacy of two doses of polatuzumab vedotin (POV) in patients with relapsed/refractory (RR) follicular lymphoma (FL).